about
Sympathetic nervous system regulation of the tumour microenvironmentThe ZNF304-integrin axis protects against anoikis in cancerRole of Increased n-acetylaspartate Levels in Cancer.2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer.DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistanceβ-blockers: a new role in cancer chemotherapy?Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.Therapeutic silencing of KRAS using systemically delivered siRNAs.XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.Erythropoietin Stimulates Tumor Growth via EphB4.Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.Src activation by β-adrenoreceptors is a key switch for tumour metastasis.Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.ATP11B mediates platinum resistance in ovarian cancer.Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.Why stress is BAD for cancer patientsCalcium-mediated oxidative stress: a common mechanism in tight junction disruption by different types of cellular stress.SnapShot: Stress and Disease
P50
Q26795614-0A2D7E30-CC1D-434C-B47B-0AC8E6935192Q28115264-2076CCAF-E6FE-4F1C-ABD7-2B8E4C45585CQ30488862-483C746D-2866-4AF6-BCA4-3B45AFE9CF88Q33956803-3B2E95A7-FAE6-420D-B930-EFFA5D6A83ACQ33989948-4AB8A40D-F70C-4024-9F4B-1B052ABB5D60Q34067050-627AD108-64AD-4F34-8343-10A2A2AC575BQ34086281-4822B808-B16A-481C-8285-E95C78686647Q34433163-0DC45537-E934-4FA1-A3A7-4D7F5094A72EQ35559932-ED771496-130A-40E8-A740-0831AB378957Q35602930-32FEE0E2-D617-4E8A-A46B-DEE417EF393DQ36275814-6498C7C9-C858-4BE8-918B-5CC74756518EQ36405508-17230076-FB88-49B6-911B-3BD23C0DE030Q36568221-8484DF20-5B4B-4E17-912C-C01841C5DD66Q36579843-4EA77B79-B851-4CCD-A0DE-7137097E206EQ36759360-9FEF2F41-B5ED-414C-B50C-3C30A119FC3EQ36768803-6799F96E-C38E-4365-8C3A-E3A42EF76821Q36793431-17123DAA-FC26-46DB-BD82-ED9D22E312DFQ36971300-634EF381-B8C9-49CF-8A57-9825ABD26504Q37062821-7B0C7B3F-A6F4-4FD1-8D2D-9A60DABB99EFQ42127137-21E1229A-19BB-49F5-BB30-82D0A592B738Q46436568-E2F82664-CA5E-4EC2-AC7F-1CA2EF909048Q61200307-7F167029-59D4-4FB5-9335-80ADFD7E1300
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Archana S. Nagaraja
@ast
Archana S. Nagaraja
@en
Archana S. Nagaraja
@es
Archana S. Nagaraja
@nl
type
label
Archana S. Nagaraja
@ast
Archana S. Nagaraja
@en
Archana S. Nagaraja
@es
Archana S. Nagaraja
@nl
prefLabel
Archana S. Nagaraja
@ast
Archana S. Nagaraja
@en
Archana S. Nagaraja
@es
Archana S. Nagaraja
@nl
P106
P1153
54397274400
P21
P31
P496
0000-0002-2851-9272